The discovery and preclinical development of selective dopamine reuptake inhibitors as potential pharmacotherapies for treating cocaine addiction are presented. The studies are based on the hypothesis that a dopamine reuptake inhibitor is expected to partially substitute for cocaine, thus decreasing cocaine self-administration and minimizing the craving for cocaine. This type of indirect agonist therapy has been highly effective for treating smoking addiction (nicotine replacement therapy) and heroin addiction (methadone). To be an effective pharmacotherapy for cocaine addiction, the potential drug must be safe, long-acting, and have minimal abuse potential. We have developed several 3-phenyltropane analogs that are potent dopamine uptake inhibitors, and some are selective for the dopamine transporter relative to the serotonin and norepinephrine transporters. In animal studies, these compounds substitute for cocaine, reduce the intake of cocaine in rats and rhesus monkeys trained to selfadminister cocaine, and have demonstrated a slow onset and long duration of action and lack of sensitization. The 3-phenyltropane analogs were also tested in a rhesus monkey selfadministration model to defi ne their abuse potential relative to cocaine. Based on these studies, 3 ␤ -(4-chlorophenyl)-2 ␤ -[3-(4 ' -methylphenyl)isoxazol-5-yl]tropane (RTI-336) has been selected for preclinical development.
A BSTRACT
The discovery and preclinical development of selective dopamine reuptake inhibitors as potential pharmacotherapies for treating cocaine addiction are presented. The studies are based on the hypothesis that a dopamine reuptake inhibitor is expected to partially substitute for cocaine, thus decreasing cocaine self-administration and minimizing the craving for cocaine. This type of indirect agonist therapy has been highly effective for treating smoking addiction (nicotine replacement therapy) and heroin addiction (methadone). To be an effective pharmacotherapy for cocaine addiction, the potential drug must be safe, long-acting, and have minimal abuse potential. We have developed several 3-phenyltropane analogs that are potent dopamine uptake inhibitors, and some are selective for the dopamine transporter relative to the serotonin and norepinephrine transporters. In animal studies, these compounds substitute for cocaine, reduce the intake of cocaine in rats and rhesus monkeys trained to selfadminister cocaine, and have demonstrated a slow onset and long duration of action and lack of sensitization. The 3-phenyltropane analogs were also tested in a rhesus monkey selfadministration model to defi ne their abuse potential relative to cocaine. Based on these studies, 3 ␤ -(4-chlorophenyl)-2 ␤ -[3-(4 ' -methylphenyl)isoxazol-5-yl]tropane (RTI-336) has been selected for preclinical development.
INTRODUCTION
Drug abuse, addiction, and dependence represent a major and increasing threat to public health. Cocaine abuse has been an epidemic in the United States since the introduction of crack in the mid-1980s. The 2003 National Survey on Drug Use and Health (NSDUH) estimated that 34.9 million Americans, aged 12 and older, have used cocaine at least once in their lifetime, that 5.9 million used cocaine in the past year, and that 2.3 million Americans are current users -some frequently, others occasionally (NSDUH report). 1 In 2002, the estimated number of cocaine-related emergency episodes totaled over 199 000. 2 While these numbers on use and cost show the magnitude of the drug abuse problem, the human suffering is incalculable. Illness, crime, domestic violence, reduced productivity, and lost opportunity are direct consequences of drug abuse. There is an increasing understanding that drug abuse is a physiologic disorder and that the need for medications for the treatment of drug abuse is tremendous. Even though several pharmacological agents have been tried on the basis of various hypotheses, none of the pharmacotherapeutic approaches has proven effective. [3] [4] [5] [6] To address this critical defi ciency, National Institute on Drug Abuse (NIDA) has made the development of an anticocaine medication a high priority.
In vitro studies have demonstrated that cocaine blocks the presynaptic uptake of dopamine, serotonin, and norepinephrine. However, it is the dopamine transporter (DAT) that is believed to be the critical recognition site for cocaine, mediating the behavioral and reinforcing effects that contribute to its abuse liability. [7] [8] [9] [10] [11] Numerous cocaine-discrimination and self-administration studies in laboratory animals support this conclusion.
A dopamine reuptake inhibitor would be expected to partially substitute for cocaine, thus decreasing cocaine selfadministration and minimizing the craving for cocaine. This type of substitution pharmacotherapy has been highly effective for treatment of nicotine addiction (nicotine gum and patch) and heroin addiction (methadone). The development of a comparable drug for cocaine addiction would allow control of the behavior of the abuser until a strategy for long-term abstinence could be developed. We have discovered novel 3-phenyltropane analogs that are dopamineselective reuptake inhibitors. It is hoped that one of these compounds will be useful as a medication for treating cocaine addicts without deleterious side effects. 12 
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Over the last several years, we synthesized several 3-phenyltropane analogs and evaluated them for binding at the dopamine, serotonin, and norepinephrine transporters (DAT, 5-HTT, and NET, respectively). Forty-seven compounds showed selectivity for the DAT relative to the 5-HTT and NET, based on their relative IC 50 values. 12 , 13 The binding affi nities of these compounds are compared with cocaine and 3-phenyltropane 2-carboxylic acid methyl ester (WIN 35,065-2) in Tables 1-4 . The compounds possess either a 4-chloro or 4-methylphenyl group at the 3 ␤ -position of the tropane ring and have an ester, amide, isoxazole, oxadiazole, benzthiazole, benzimidazole, or thiazole group in the 2 ␤ -position. The 15 RTI compounds shown in Table 1 have various ester groups in the 2 ␤ position of the tropane ring. The affi nity for the dopamine transporter varies from 0.96 nM for RTI-190 to 9.6 nM for RTI-145. The affi nities for the ten 2 ␤ amides listed in Table 2 vary from 0.75 nM for RTI-227 to 6.95 nM for RTI-156. Note the very high DAT selectivity for RTI-147, RTI-214, and RTI-218. The affi nities for the 2 ␤ -isoxazoles listed in Table 3 vary from 0.50 nM for RTI-334 to 8.7 nM for RTI-371. Table 4 compares the inhibition of radioligand binding at the dopamine, norepinephrine, and serotonin transporters to those of cocaine and WIN 35,065-2 for 6 different other 2 ␤ heterocyclic analogs. Together, these compounds possess sufficient structural diversity to provide considerable variation in physicochemical properties. Furthermore, given their close structural similarity to other RTI compounds with known behavioral activity (RTI-32, -55, -113, -121, and -130), 14 , 15 it was expected that these compounds would both cross the blood-brain barrier and possess behavioral activity.
In designing a potential pharmacotherapy for cocaine abuse, other pharmacological activities must also be considered.
Evidence from both animal and human studies suggests that the pharmacokinetic and pharmacodynamic properties of cocaine are important in reinforcement. [16] [17] [18] [19] [20] [21] [22] It is well known that cocaine gets into the brain quickly after peripheral administration and produces a " high " in 1 to 4 minutes. [16] [17] [18] This relatively rapid onset of action apparently contributes to cocaine ' s high effi cacy as a reinforcer. 
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that differences in the rate at which cocaine is administered determine its ability to produce psychomotor sensitization and presumably the associated adaptation in the brains of rats. Thus, a clinical candidate should also show low sensitization. In addition, a long duration of action would be desirable. Volkow et al 24 used positron emission tomography (PET) studies to show that the rate of clearance for the relatively more potent methylphenidate was signifi cantly slower than for cocaine and suggested that this could account for the much lesser abuse of methylphenidate than cocaine despite their otherwise similar pharmacological properties. Furthermore, in selecting a candidate for further development, it is preferable for the compound to be orally available and no more stimulatory than cocaine at peak doses. As a direct test of the compound's potential effi cacy in humans, the compound should substitute for cocaine in animal models and should block cocaine self-administration in both rats and rhesus monkeys.
In order to identify 3-phenyltropane analogs that possessed pharmacological properties suitable for further consideration, the compounds listed in Tables 1 to 4 were fi rst evaluated for locomotor activity in mice 25 and cocaine discrimination in rats; several compounds were also tested in in vitro toxicity assays listed in Table 5 . The 5 compounds listed in Tables 6 and 7 showed the most favorable overall balance of pharmacological properties and toxicity results. It is interesting to note that all 5 compounds are 3 ␤ -phenyltropane 2 ␤ -1,2-(isoxazole) analogs (see Table 3 for structures). Examination of the data in Table 6 shows that cocaine produced its greatest stimulation in hour 1, and that by hour 3 the effect was gone. In contrast, all 2 ␤ -1,2-(isoxazoles) had their largest effect in hours 2 to 4. The ED 50 values for the 2 ␤ -1,2-(isoxazoles) ranged from 0.9 mg/kg for RTI-354 to 12.8 mg/kg for RTI-386. RTI-176 and RTI-354 produced greater stimulation than cocaine in 25 mg/kg in the locomotor activity and drug-discrimination test after oral administration (unpublished results, Carroll 2004) and also reduced cocaine self-administration after oral administration in a rat model of self-administration, was studied for its effect on cocaine self-administration in rhesus monkeys. Pretreatment intravenously (IV) with RTI-177 produced a dose-related reduction in cocaine self-administration in rhesus monkeys trained to selfadminister cocaine (0.1 and 0.3 mg/kg) under a secondorder schedule of IV drug delivery. The ED 50 was 0.11 mg/kg, which is an order of magnitude more potent than their peak hours; RTI-177 had about the same stimulation as cocaine; and RTI-336 and RTI-386 were less stimulatory than cocaine.
All fi ve 3 ␤ -(1,2-isoxazoles) selected for further evaluation showed full generalization to the cocaine cue ( ≥ 75% of rats choosing the cocaine lever), with the ED 50 values ranging from 0.82 mg/kg for RTI-354 to 11.0 mg/kg for RTI-386; the ED 50 for cocaine was 2.64 mg/kg. below the threshold (<10%) of detection, whereas ED 50 doses resulted in DAT occupancies of 73% and 67%, respectively. 26 RTI-177 and GBR 12909 were substituted for cocaine in drug self-administration studies in order to characterize their reinforcing effects. Both RTI-177 and GBR 12909 reliably maintained drug self-administration at levels greater than those maintained by saline in all subjects ( Figure 1 ) . Moreover, the shape of the dose-effect curves resembled an inverted U-shape function typical of psychomotor stimulants. However, rates of responding were lower than those maintained by the training dose of cocaine (0.1 mg/kg/infusion) in 2 of 3 subjects substituted with GBR 12909 and in all 3 subjects substituted with RTI-177.
In acute toxicity studies in male rats, 3 Table 9 ). These results suggested that RTI-336 was a better candidate than RTI-177 for further preclinical development. Similar to RTI-177, RTI-336 showed oral activity in the locomotor activity and drug-discrimination test with ED 50 s of 14.4 and 3.54 mg/kg, respectively. Of GBR 12909, which has an ED 50 of 1.29 mg/kg ( Table 8 ) . 26 PET neuroimaging studies revealed that the ED 10 doses of RTI-177 and GBR 12909 resulted in DAT occupancies E202 importance, RTI-336 showed very low sensitization relative to cocaine. RTI-336 reduced cocaine self-administration in a rat model of self-administration (unpublished results, Howell 2004), and in preliminary rhesus monkey studies, RTI-336 produced dose-dependent reductions in cocaine self-administration in 4 subjects and was equally effective at both maintenance doses of cocaine (0.1 and 0.3 mg/kg/ injection). Food-maintained behavior was suppressed at the same doses of RTI-336 that suppressed cocaine-maintained behavior. Positron emission tomography (PET) imaging was conducted in the same subjects to determine the level of DAT occupancy associated with behaviorally-relevant doses of RTI-336. Doses of RTI-336 that reduced cocaine-maintained behavior by 50% (ED 50 ) resulted in 90% DAT occupancy for the group of 4 subjects. Daily food intake, body weight, and behavior were normal.
CONCLUSION
In summary, RTI-336 showed locomotor activity less than that of cocaine with no sensitization. It was orally active in both the locomotor assay in mice and drug discrimination tests in rats and possessed an excellent therapeutic ratio. RTI-336 reduced cocaine self-administration in both rat and rhesus monkey models and showed slow onset and long duration of action in rodent and monkey models. These preliminary studies in rhesus monkeys showed that RTI-336 was effective in suppressing cocaine self-administration at doses that had no obvious adverse behavioral effects. Varying the maintenance dose of cocaine had no infl uence on the effectiveness of drug pretreatments. There was no evidence of selective reductions in cocaine self-administration compared with food-maintained behavior. High levels of DAT occupancy were required to produce robust reduction in cocaine use. 
